Search company, investor...

Founded Year




Total Raised


Date of IPO


Market Cap


Stock Price




About Veracyte

Veracyte operates as a molecular diagnostics company. It focuses on discovering, developing, and commercializing molecular diagnostic solutions that enable physicians to make informed treatment decisions at an early stage in patients' treatment. It was founded in 2008 and is based in South San Francisco, California.

Headquarters Location

6000 Shoreline Court Suite 300

South San Francisco, California, 94080,

United States




Research containing Veracyte

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Veracyte in 1 CB Insights research brief, most recently on Jun 2, 2022.

Veracyte Patents

Veracyte has filed 52 patents.

The 3 most popular patent topics include:

  • rare diseases
  • lung disorders
  • syndromes
patents chart

Application Date

Grant Date


Related Topics




Molecular biology, Genetics, Lung disorders, Rare diseases, Autoimmune diseases


Application Date


Grant Date



Related Topics

Molecular biology, Genetics, Lung disorders, Rare diseases, Autoimmune diseases



Latest Veracyte News

Real-World Data Presented at SUO 2023 Show that Veracyte's Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress

Dec 1, 2023

( Veracyte, Inc. announced that new data presented today at the 24th Annual Meeting of the Society of Urologic Oncology highlight clinical observations and translational research conducted by users of the company’s Decipher Prostate Genomic Classifier. These independent, real-world studies provide further evidence supporting the clinical...

Veracyte Frequently Asked Questions (FAQ)

  • When was Veracyte founded?

    Veracyte was founded in 2008.

  • Where is Veracyte's headquarters?

    Veracyte's headquarters is located at 6000 Shoreline Court, South San Francisco.

  • What is Veracyte's latest funding round?

    Veracyte's latest funding round is IPO.

  • How much did Veracyte raise?

    Veracyte raised a total of $79M.

  • Who are the investors of Veracyte?

    Investors of Veracyte include Kleiner Perkins Caufield & Byers, Versant Ventures, Domain Associates, TPG Biotech and GE Ventures.

  • Who are Veracyte's competitors?

    Competitors of Veracyte include Cofactor Genomics, Numares, Qualisure, Stratipath, ARTIDIS and 7 more.


Compare Veracyte to Competitors

Oncology Research Therapeutics

Oncology Research Therapeutics, Inc. is dedicated to providing and discovering cancer diagnostics that improve the lives of patients suffering from a wide array of cancers. They also provide R&D services that improve drug development for the Biotech and Pharmaceutical industries.


Proacta is a clinical-stage, biopharmaceutical company focused on addressing unmet needs in the field of cancer with current efforts directed towards the development of hypoxia-activated prodrugs that target treatment-resistant cancer cells.

Esperance Pharmaceuticals

Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.

CoImmune Logo

CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.

Occam BioLabs

Occam BioLabs is a company engaged in developing technologies for detection and quantification of biomolecules. The company is focused on three general areas of research and development: design and prototyping of electro-optical devices for analysis of biological samples, developing analytic reagents and kits for emergent biomedical fields, providing expertise services for assay optimization including high-throughput quantification in the pharmaceutical industry.

Rimon Therapeutics

Rimon Therapeutics, through the application of its polymer chemistry platform, is developing therapeutics to address unmet needs in important disease indicators with large markets. Rimon's therapeutic polymers - trademarked Theramers - are in that they deliver therapeutic effect without incorporating or releasing drugs. Theramers are intended to be used as solids-scaffolds, microbeeds and coatings - acting locally, without systemic consequences.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.